

Celsion Corporation (NASDAQ/CLSN)

June 25, 2020

BUY: Celsion – Raises \$9.3M (~\$26M in Cash on Hand), Optima Next, Raising Price Target from \$4.0 to \$5.0 Based on Less Than Expected Dilution.

Celsion announces that the independent Data Monitoring Committee (iDMC) is scheduled to meet during H1 of July to conduct the second pre-planned interim safety and efficacy analysis of the Phase III OPTIMA Study with ThermoDox plus RFA (radiofrequency ablation) in patients with hepatocellular carcinoma (HCC), or primary liver cancer. Data lock for the second pre-specified interim analysis occurred during April 2020 after the prescribed minimum number of events of 158 patient deaths was reached. We also note the company raised \$9.3M (net) by selling 2.7M shares, which brings the Pro-forma cash balance to approximately \$26M.

Jason H. Kolbert
 Head of Healthcare Research
 646-465-6891
 jkolbert@dawsonjames.com

Investment Highlights

What's Next? The Independent Data Monitoring Committee (iDMC) is expected to meet in July to conduct the second interim analysis. Celsion expects to announce iDMC recommendations as soon as possible after the meeting. The hazard ratio for success at 158 deaths is 0.70, which represents a 30% reduction in the risk of death compared with RFA alone. This compares favorably with the hazard ratio of 0.65 observed in the prospective HEAT Study subgroup upon which the OPTIMA Study is based.

As a reminder, the independent Data Monitoring Committee (iDMC) unanimously recommends the OPTIMA Study (Liver Cancer) continue according to protocol. The reported interim analysis reviewed 128 events (from 556 patients) or >60% of the total number required for the final analysis. The hazard ratio for success at 128 events is approximately 0.637, which represents a 57% improvement in immediate survival vs. control. We note that this is consistent with the 0.65 hazard ratio, or 55% improvement seen in the prospective HEAT Study subgroup (which OPTIMA is based upon), which demonstrated a two-year overall survival advantage and a median time to death of more than 7 ½ years.

Valuation: We adjust our model for the recent raise, which was less than we had forecast. As a result, our out-year share count drops, driving our valuation higher from \$4.0 to \$5.0. Celsion's success as a company is dependent on the clinical outcomes for ThermoDox and GEN-1. For the purposes of our model we project timelines through the year 2030. Our therapeutic models are risk-adjusted. For the U.S. for ThermoDox we use just a 75% risk rate (25% probability of success), and in China we reduce this to 50%. For GEN-1 we assume just a 10% probability of success. Our models factor in assumed financings and use a fully diluted out-year (2030) share count. We triangulate FCFF, discounted EPS, and sum-of-the-parts models. We then averaged and equally weighted each model to derive the NPV and round to the nearest whole number to set our target price.

Risk Analysis: (1) commercial; (2) regulatory; (3) clinical; (4) manufacturing; (5) financial; (6) liability; and (7) intellectual property. We review these and other risks in the risk section of this report.

Current Price				\$3.99
Price Target				\$ 5.00
Estimates	F2019A	F2020E	F2021E	
Expenses (\$000s)	\$ 21,065	\$ 21,701	\$ 15,287	
1Q January	\$ 4,986	\$ 4,891	\$ 3,669	
2Q April	\$ 5,695	\$ 5,530	\$ 3,822	
3Q July	\$ 5,513	\$ 5,530	\$ 3,822	
4Q October	\$ 4,873	\$ 5,751	\$ 3,974	
	F2019A	F2020E	F2021E	
EPS (diluted)	\$ (0.77)	\$ (0.56)	\$ (0.33)	
1Q January	\$ (0.12)	\$ (0.20)	\$ (0.08)	
2Q April	\$ (0.29)	\$ (0.12)	\$ (0.08)	
3Q July	\$ (0.25)	\$ (0.12)	\$ (0.08)	
4Q October	\$ (0.11)	\$ (0.12)	\$ (0.09)	
EBITDA/Share				
EV/EBITDA (x)				
Stock Data				
52-Week Range	\$0.69	-	\$6.50	
Shares Outstanding (mil.)				31.9
Market Capitalization (mil.)				\$127
Enterprise Value (mil.)				\$135
Debt to Capital				6%
Book Value/Share				\$1.55
Price/Book				2.7
Average Three Months Trading Volume (K)				392
Insider Ownership				7.1%
Institutional Ownership				8.5%
Short interest (mil.)				4.2%
Dividend / Yield				\$0.00/0.0%



Modeling Assumptions:

- Price & Timing for ThermoDox.** We assume a price of \$40,000 for ThermoDox in Hepatocellular Carcinoma in both the United States and China with commercialization by 2023, which could prove conservative. We apply a 75% risk cut, or 25% probability of success in our U.S. model and 50% in our China model for conservatism. Clinical success suggests our valuation could be too low. We assume a modest market penetration that ramps up over five years as the patient population grows and these numbers also could prove to be too conservative.
- Incidence and Prevalence of HCC:** Hepatocellular Carcinoma has the fourth highest mortality rate of all cancers with a median survival from time of diagnosis at less than three years. The five-year survival rate is less than ten percent, and less than twenty percent of early and intermediate stage patients are eligible for curative surgery. HCC has a global incidence of about 755,000 growing at 3% annually. The U.S. incidence is about 35,000, and the EU incidence is about 65,000, while China remains the largest market with an incidence over 375,000.
- Price & Timing for Gen-1.** We also assume a price of \$40,000 for GEN-1 in Ovarian Cancer with commercialization by 2025. We apply a 90% risk cut or 10% probability of success in our model and assume a modest market penetration.
- Incidence and Prevalence of Ovarian Cancer:** Ovarian Cancer holds the fifth highest mortality rate of all cancers among women with a five-year survival rate for all stages of less than 50%. Over 70% of women are diagnosed in advanced stages (III/IV), and only 15% of those diagnosed with localized cancer are eligible for potentially curative surgery. The survival rate is significantly reduced in non-localized cancer, and the most common site of recurrence is the abdomen. Intraperitoneal-administered therapy is an important clinical strategy. Ovarian Cancer remains the 8th most diagnosed cancer among women with a global incidence rate of 225,000. The incidence rate in the US is about 22,280 and 100,000 in developed countries.
- Patient Eligibility:** For the Phase 3 OPTIMA Study Design, patient's eligibility includes having nonresectable HCC, singles lesions, lesion > 3cm but not > 7cm, treatment naïve, and child-pugh A. In ovarian cancer, over 75% of incidence is within stage III/IV, and we assume that only the platinum-resistant proportion of ovarian cancer patients will be eligible for treatment.

Exhibit 1a. Therapeutic Models

Hepatocellular Carcinoma, (US) (ThermoDox)	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Incidence	30,000	31,200	32,448	33,746	35,096	36,500	37,960	39,478	41,057	42,699	44,407	46,184	48,031	49,952
Increase in incidence	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%	4%
Patients with single lesion receiving RF only (20%)	6,000	6,240	6,490	6,749	7,019	7,300	7,592	7,896	8,211	8,540	8,881	9,237	9,606	9,990
Patients with 3-7cm lesion meeting ThermoDox criteria (20%)	6,000	6,240	6,490	6,749	7,019	7,300	7,592	7,896	8,211	8,540	8,881	9,237	9,606	9,990
Total RF patients that could benefit from ThermoDox	12,000	12,480	12,979	13,498	14,038	14,600	15,184	15,791	16,423	17,080	17,763	18,473	19,212	19,981
% Market share	0%	0%	0%	0%	0%	0%	1%	2%	3%	4%	5%	5%	5%	5%
Total patients receiving ThermoDox	0	0	0	0	0	0	151,84	316	493	683	888	924	961	999
Cost of therapy	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,400	\$ 40,804	\$ 41,212	\$ 41,624	\$ 42,040	\$ 42,461	\$ 42,885
Change in cost of therapy							0%	1%	1%	1%	1%	1%	1%	1%
Sales	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 6,074	\$ 12,759	\$ 20,108	\$ 28,166	\$ 36,989	\$ 46,789	\$ 56,944	\$ 67,564
Risk Adjusted							75%	75%	75%	75%	75%	75%	75%	75%
Total Revenue (Millions)							1,518	3,190	5,028	7,039	9,242	9,708	10,197	10,711
Hepatocellular Carcinoma, (China) (ThermoDox)	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Incidence	378,000	389,340	401,020	413,051	425,442	438,206	451,352	464,892	478,839	493,204	508,000	523,240	538,938	555,108
Increase in incidence	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%	3%
Patients with single lesion receiving RF only (20%)	75,600	77,868	80,204	82,610	85,088	87,641	90,270	92,978	95,768	98,641	101,600	104,648	107,788	111,021
Patients with 3-7cm lesion meeting ThermoDox criteria (20%)	75,600	77,868	80,204	82,610	85,088	87,641	90,270	92,978	95,768	98,641	101,600	104,648	107,788	111,021
Total RF patients that could benefit from treatment	200,000	202,000	204,020	206,060	208,121	210,202	212,304	214,427	216,571	218,737	220,924	223,134	225,365	227,619
% Market share	0%	0%	0%	0%	0.00%	0.00%	0.5%	0.5%	1%	1%	1.5%	2%	2.5%	3%
Total patients receiving treatment	-	-	-	-	-	-	1,082	1,072	2,166	2,187	3,314	4,463	5,634	6,829
Cost of therapy	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,400	\$ 40,804	\$ 41,212	\$ 41,624	\$ 42,040	\$ 42,461	\$ 42,885
Change in cost of therapy							0%	1%	1%	1%	1%	1%	1%	1%
Sales							42,461	44,181	88,370	90,146	137,937	187,813	239,229	292,848
Risk Adjusted							50%	50%	50%	50%	50%	50%	50%	50%
Total Revenue (Millions)							21,230	22,090	44,185	45,073	88,968	93,806	119,815	146,423
Ovarian Cancer (Gen-1)	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Incidence	225,000	227,250	229,523	231,818	234,136	236,477	238,842	241,230	243,643	246,079	248,540	251,025	253,536	256,071
Change in incidence	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Patients Population in US and developed countries	122,280	123,503	124,739	125,985	127,245	128,518	129,803	131,101	132,412	133,738	135,079	136,424	137,783	139,166
Platinum resistant population in Europe and US	30,570	30,876	31,184	31,496	31,811	32,129	32,451	32,775	33,103	33,434	33,768	34,106	34,447	34,792
% Market share	0%	0%	0%	0%	0%	0%	0%	0%	0%	4%	8%	10%	11%	12%
Total patients receiving treatment	-	-	-	-	-	-	-	-	662	1,337	2,701	3,411	3,789	4,175
Cost of therapy	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,400	\$ 40,804	\$ 41,212	\$ 41,624	\$ 42,040
Change in cost of therapy									0%	1%	1%	1%	1%	1%
Sales									26,462	54,029	110,231	140,558	157,721	175,516
Risk adjustment									90%	90%	90%	90%	90%	90%
Total Revenue (Millions)									2,648	5,403	11,023	14,056	15,772	17,552
Glioblastoma (Gen-1)	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Incidence	22,850	22,850	23,079	23,309	23,542	23,776	24,016	24,256	24,496	24,743	24,991	25,241	25,493	25,748
Change in incidence	0%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Patients eligible for treatment, insurance coverage, 75%	-	-	-	-	-	-	-	-	30%	30%	30%	30%	30%	30%
% Market share	0%	0%	0%	0%	0%	0%	0%	0%	5%	10%	15%	15%	15%	15%
Total patients receiving treatment	-	-	-	-	-	-	-	-	367	742	1,125	1,136	1,147	1,159
Annual cost of treatment	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,000	\$ 40,400	\$ 40,804	\$ 41,212	\$ 41,624	\$ 42,040
Increase in price									0%	1%	1%	1%	1%	1%
Sales									14,699	29,969	45,887	46,810	47,751	48,710
Risk adjustment									100%	100%	100%	100%	100%	100%
Total Revenue (Millions)									100	200	300	300	300	300
Bladder (ThermoDox)	2017E	2018E	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Incidence	80,470	82,079	83,721	85,395	87,103	88,845	90,622	92,435	94,283	96,169	98,092	100,054	102,055	104,097
Change in incidence	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%	2%
Patients Population in US	700,000	714,000	728,280	742,846	757,703	772,857	788,314	804,080	820,162	836,565	853,296	870,362	887,769	905,525
Patients eligible for treatment	70,000	71,400	72,828	74,285	75,770	77,286	78,831	80,408	82,019	83,666	85,330	87,036	88,777	90,552
% Market share	0%	0%	0%	0%	0%	0%	0%	0%	5%	10%	15%	15%	15%	15%
Total patients receiving treatment	-	-	-	-	-	-	-	-	4,100.81	8,366	12,799	13,055	13,317	13,583
Cost of therapy	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000	\$ 20,000	\$ 30,000	\$ 30,300	\$ 30,603	\$ 30,909	\$ 31,216	\$ 31,530
Increase in price									0%	1%	1%	1%	1%	1%
Sales									123,024	253,479	391,701	403,531	415,717	428,272
Risk adjustment									100%	100%	100%	100%	100%	100%
Total Revenue (Millions)									100	200	300	300	300	300

Source: Dawson James

VALUATION

Our valuation is derived by our revenue projections for ThermoDox and GEN-1 in their respective indications of Hepatocellular carcinoma and ovarian cancer. We do not model any potential revenues from these programs until at least 2023 and project our model through the year 2030. Our therapeutic models are risk-adjusted. For the U.S. for ThermoDox we use just a 75% risk rate (25% probability of success), and in China we reduce this to 50%. For GEN-1 we assume just a 10% probability of success. Our models factor in assumed financings and use a fully diluted out-year (2030) share count. We triangulate FCF, discounted EPS, and sum-of-the-parts models. We then averaged and equally weighted each model to derive the NPV and round to the nearest whole number to set our target price. Investors should recognize that this modeling exercise, which models out for ten years, while projected based on the current data and estimates, is limited in its ability to predict a 12-month target. The price of the stock will ultimately be driven near term by factors such as news flow, early trial data, and cyclic concerns of financings (dilution).

Exhibit 1. Free Cash Flow Model

Average	\$	5.09
Price Target	\$	4.41
Year		2020

DCF Valuation Using FCF (mln):

units ('000)	2019E	2020E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
EBIT	(18,668)	(23,157)	(16,450)	(17,215)	1,319	2,881	25,373	29,939	58,661	86,667	114,556	141,073
Tax Rate	0%	0%	0%	0%	0%	5%	10%	15%	20%	25%	26%	27%
EBIT(1-)	(18,668)	(23,157)	(16,450)	(17,215)	1,319	2,737	22,836	25,449	46,929	65,000	84,771	102,984
CapEx	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation	-	-	-	-	-	-	-	-	-	-	-	-
Change in NWC	-	-	-	-	-	-	-	-	-	-	-	-
FCF	(18,668)	(23,157)	(16,450)	(17,215)	1,319	2,737	22,836	25,449	46,929	65,000	84,771	102,984
PV of FCF	(21,468)	(23,157)	(14,305)	(13,017)	868	1,565	11,353	11,002	17,642	21,249	24,097	25,456
Discount Rate	15%											
Long Term Growth Rate	1%											
Terminal Cash Flow	742,953											
Terminal Value YE2030	183,647											
NPV	224,932											
NPV-Debt												
Shares out (thousands)	50,955	2030E										
NPV Per Share	\$	4.41										

Source: Dawson James

Exhibit 2. Discounted EPS Model

Current Year	2020
Year of EPS	2030
Earnings Multiple	10
Discount Factor	15%
Selected Year EPS	\$ 2.03
NPV	\$ 5.01

Source: Dawson James Estimates

		Discount Rate and Earnings Multiple Varies, Year is Constant					
		2030 EPS					
Earnings Multiple		5%	10%	15%	20%	25%	30%
		1		\$1.24	\$0.78	\$0.50	\$0.33
5		\$6.22	\$3.90	\$2.50	\$1.64	\$1.09	\$ 0.73
10		\$12.43	\$7.81	\$5.01	\$3.27	\$2.17	\$ 1.47
15		\$18.65	\$11.71	\$7.51	\$4.91	\$3.26	\$ 2.20
20		\$24.86	\$15.61	\$10.01	\$6.54	\$4.35	\$ 2.94
25		\$31.08	\$19.52	\$12.51	\$8.18	\$5.44	\$ 3.67
30		\$37.30	\$23.42	\$15.02	\$9.81	\$6.52	\$ 4.41
35		\$43.51	\$27.33	\$17.52	\$11.45	\$7.61	\$ 5.14

Source: Dawson James

Exhibit 3. Sum of the Parts Model

	LT Gr	Discount Rate	Yrs. to Mkt	% Success	Peak Sales MM's	Term Val
ThermoDox/HCC (US)	1%	15%	4	65%	\$11	\$76.51
NPV						\$0.37
Thermodox/HCC (China)	1%	15%	4	65%	\$146	\$1,046
NPV						\$5.03
Gen1/Ovarian Cancer (US)	1%	15%	6	65%	\$18	\$125
NPV						\$0.46
Net Margin						65%
MM Shrs OS (2030E)						50
Total						\$5.86

Source: Dawson James

Risk Analysis

Investment Risk: The company faces multiple investment risks from product management, market share adoption, and commercialization to regulatory and competitive environment associated risks.

Clinical and regulatory risk: Celsion is currently in the process of completing its FDA clinical trials. There is no assurance that their product will be approved by the FDA and that even if approved if it will be reimbursed by insurance or successfully commercialized.

Commercial risk: The focus of the company is on successfully developing their products and eventually bring them to the mass market. We can make no assurances that the company will be able to achieve a critical level of market share to become profitable in this indication and or in additional planned indications.

Employee risk: Celsion's core management team is experienced and has clear expectations for the future of the company. Celsion plans to bring their proposed products to market as efficiently as possible, and their success will depend heavily upon the experience, abilities, and continued services of its senior officers, sales staff, and key scientific personnel.

Financial risk: Celsion may need to raise additional capital in the marketplace to continue to fund operations through more trials and eventually an NDA and possible commercial launch. There can be no assurances that the company will be able to successfully raise capital and do so on favorable terms.

Intellectual property risk: Celsion may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and the company may infringe on third party's patents.

Reimbursement and insurance payment risk: Insurance payment for products may be an additional hurdle for adoption.

Exhibit 4. Income Statement

Celsion Corporation.: Income Statement (\$000)																					
:-YE December 31	2018A	2019A	1Q20A	2Q20E	3Q20E	4Q20E	2020E	1Q21E	2Q21E	3Q21E	4Q21E	2021E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E
Product sales																					
Hepatocellular Carcinoma; (US) (ThermoDox)	-	-	-	-	-	-	-	-	-	-	-	-	-	1,518	3,190	5,026	7,039	9,242	9,708	10,197	10,711
Hepatocellular Carcinoma; (China) (ThermoDox)	-	-	-	-	-	-	-	-	-	-	-	-	-	21,230	22,090	44,185	45,073	68,968	93,806	119,615	146,423
Ovarian Cancer (Gen-1)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,648	5,403	11,023	14,056	15,772	17,552
Glioblastoma (pre-clinical)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-Muscle Invasive bladder cancer (Pre-clinical)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licensing Revenue	500	500	125				125														
Total Product Sales	500	500	125				125							22,749	25,280	51,859	57,515	89,234	117,570	145,584	174,686
Operating Expenses																					
Cost of Goods Sold														3,412	3,539	6,742	6,902	8,923	8,230	7,279	8,734
														15%	14%	13%	12%	10%	7%	5%	5%
Research and Development	11,866	13,065	3,052	3,430	3,430	3,567	13,719	3,457	3,601	3,601	3,745	14,405	15,125	15,881	16,675	17,509	18,384	19,303	20,269	21,282	22,346
General and Administrative	9,700	8,000	1,839	2,100	2,100	2,184	8,400	212	221	221	229	882	926	972	1,021	1,072	1,126	1,182	1,241	1,303	1,368
														4%							
Acquisition Costs																					
Total expenses	21,565	21,065	4,891	5,530	5,530	5,751	22,119	3,669	3,822	3,822	3,974	15,287	16,051	20,266	21,235	25,323	26,412	29,409	29,740	29,864	32,449
Operating Income (Loss)	(21,065)	(20,565)	(4,766)	(5,530)	(5,530)	(5,751)	(21,994)	(3,669)	(3,822)	(3,822)	(3,974)	(15,287)	(16,051)	2,483	4,045	26,536	31,103	59,825	87,830	115,720	142,237
Investment income, net	354	501	(41)	(41)	(41)	(41)	(165)	(41)	(41)	(41)	(41)	(165)	(165)	(165)	(165)	(165)	(165)	(165)	(165)	(165)	(165)
Interest expense	(712)	(1,393)	(339)	(339)	(339)	(339)	(1,357)	(339)	(339)	(339)	(339)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)	(1,357)
Gain (loss) from change in valuation of common stock warrant liability																					
Loss from impairment of in-process research and development	(4,510)																				
Other income (expense)	0	29	88	88	88	88	353	88	88	88	88	353	353	353	353	353	353	353	353	353	353
Loss from valuation of earn-out milestone liability	3,631	3,189	1	1	1	1	6	1	1	1	1	6	6	6	6	6	6	6	6	6	6
Fair value of warrants issued in connection with amendment		(400)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income	(1,237)	29	(291)	(291)	(291)	(291)	(1,164)	(291)	(291)	(291)	(291)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)	(1,164)
Pretax Income	(22,302)	(18,668)	(5,057)	(5,821)	(5,821)	(6,042)	(23,157)	(3,960)	(4,113)	(4,113)	(4,265)	(16,450)	(17,215)	1,319	2,881	25,373	29,939	58,661	86,667	114,556	141,073
Income Tax Benefit (Provision)	10,419	1,816												-	144	2,537	4,491	11,732	21,667	29,785	38,090
Tax Rate														0%	5%	10%	15%	20%	25%	26%	27%
GAAP Net Income (loss)	(11,883)	(16,852)	(5,057)	(5,821)	(5,821)	(6,042)	(23,157)	(3,960)	(4,113)	(4,113)	(4,265)	(16,450)	(17,215)	1,319	2,737	22,836	25,449	46,929	65,000	84,771	102,984
Deemed dividend related to warrant modification																					
Net Income attributable to common shareholders(loss)	(11,883)																				
Basic and Diluted	(0.68)																				
GAAP-EPS	(0.68)	(0.77)	(0.20)	(0.12)	(0.12)	(0.12)	(0.56)	(0.08)	(0.08)	(0.08)	(0.09)	(0.33)	(0.34)	0.1	0.1	0.5	0.5	0.9	1.3	1.7	2.0
GAAP EPS (dil)		(0.77)	(0.20)	(0.12)	(0.12)	(0.12)	(0.56)	(0.08)	(0.08)	(0.08)	(0.09)	(0.33)	(0.34)	0.1	0.1	0.5	0.5	0.9	1.3	1.7	2.0
Wgtd Avg Shrs (Bas) - '000s	17,583	21,832	25,804	46,901	49,648	49,698	43,013	49,747	49,797	49,847	49,897	49,822	49,947	50,072	50,197	50,323	50,448	50,575	50,701	50,828	50,955
Wgtd Avg Shrs (Dil) - '000s	17,583	21,832	25,804	46,901	49,648	49,698	43,013	49,747	49,797	49,847	49,897	49,822	49,947	50,072	50,197	50,323	50,448	50,575	50,701	50,828	50,955

Source: Dawson James estimates

Companies mentioned in this report

Celsion Corporation

Important Disclosures:

Price Chart:



Price target and rating changes over the past three years:

- Initiated – Buy – August 5, 2019 – Price Target \$4.00
- Update – Buy – August 14, 2019 – Price Target \$4.00
- Update – Buy – August 19, 2019 – Price Target \$4.00
- Update – Buy – November 5, 2019 – Price Target \$4.00
- Update – Buy – February 6, 2020 – Price Target \$4.00
- Update – Buy – April 16, 2020 – Price Target \$4.00
- Update – Buy – May 18, 2020 – Price Target \$4.00
- Update – Buy – June 25, 2020 – Price Target Increase from \$4.00 to \$5.00

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject company(s). The Firm has NOT engaged in investment banking relationships with CLSN in the prior twelve months, as a manager or co-manager of a public offering and has NOT received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has received other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of May 31, 2020, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "STOCK VALUATION" and "RISK ANALYSIS" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Rating Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Ratings Distribution	Company Coverage		Investment Banking	
	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	23	92%	3	13%
Market Perform (Neutral)	2	8%	1	50%
Market Underperform (Sell)	0	0%	0	0%
Total	25	100%	4	16%

Analyst Certification:

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.